Topical Trichosanthis Radix Water Extract Attenuates Atopic Dermatitis-Like Inflammation by Modulating JAK/STAT and MEK/ERK Signaling
Background
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation, skin barrier dysfunction, and intense pruritus. Current treatments often fall short in long-term management or carry significant side effects. A key driver of AD pathogenesis is the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, which mediates cytokine responses central to inflammation. Traditional remedies like Trichosanthis Radix (TR), known for clearing heat and reducing swelling, offer a promising avenue for novel AD therapies by targeting these inflammatory pathways.
Study Design
Researchers evaluated Trichosanthis Radix (TR) water extract's activity against atopic dermatitis using an integrated approach. They performed network pharmacology to identify 25 overlapping TR targets and AD-associated genes, and standardized the extract using HPLC-ELSD to quantify L-citrulline as a marker compound. Biological effects were then validated in vivo using a DNCB-induced murine dermatitis model and in vitro with TNF-α/IFN-γ-stimulated HaCaT keratinocytes. The murine study involved topical application of TR extract, with effects compared across doses, focusing on dermatitis severity, epidermal changes, and inflammatory markers.
Results
Network analysis revealed 25 overlapping genes forming an interaction module enriched for immune signaling and lipid/nuclear receptor pathways. HPLC-ELSD successfully detected and quantified L-citrulline for extract standardization. Topical Trichosanthis Radix water extract consistently reduced dermatitis severity, attenuated epidermal hyperplasia, and decreased dermal mast cell accumulation in the murine model, with more pronounced effects at the higher dose. TR also significantly lowered lesional chemokine transcripts, specifically CCL17/TARC and CCL5/RANTES, and was associated with reduced NLRP3 and IL-1β expression. Furthermore, TR suppressed DNCB-induced phosphorylation of MEK/ERK and JAK2-STAT1, and decreased p-STAT1 immunofluorescence. In HaCaT cells, TR similarly attenuated cytokine-induced inflammatory effectors and phosphorylation of MEK/ERK and STAT1.
Key Findings
- Trichosanthis Radix water extract significantly reduced dermatitis severity and epidermal hyperplasia in a murine AD model.
- Topical TR decreased dermal mast cell accumulation and lowered
CCL17/TARCandCCL5/RANTESchemokine transcripts. - TR treatment was associated with reduced
NLRP3andIL-1βexpression in lesional skin. - TR suppressed
DNCB-induced phosphorylation ofMEK/ERKandJAK2-STAT1in vivo and in vitro. - L-citrulline was identified and quantified as a marker compound for TR extract standardization.
Why It Matters
Trichosanthis Radix water extract presents a promising natural compound for atopic dermatitis management, offering a multi-targeted approach to inflammation. This study provides preclinical validation for its traditional use, suggesting it could potentially alleviate symptoms by modulating key inflammatory pathways like JAK/STAT and MEK/ERK. For individuals seeking alternative or complementary therapies, a standardized topical TR extract could offer a new option to reduce skin inflammation and improve barrier function. Further research is needed to isolate active constituents and translate these findings into human clinical trials, but the identified mechanisms provide a strong foundation for developing a novel, potentially safer, topical treatment protocol.